

Date: 9th February, 2023

To,
The Manager,
Department of Corporate Services,
BSE Limited
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip Code: 506235

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051
Trading Symbol: ALEMBICLTD

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter and nine months period ended 31st December, 2022.

We enclose herewith the following:

- 1) Consolidated Unaudited Financial Results of the Company for the quarter and nine months period ended 31st December, 2022.
- 2) Standalone Unaudited Financial Results of the Company for the quarter and nine months period ended 31st December, 2022.
- 3) Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 4:00 p.m. and the time of conclusion was 5:00 p.m.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully,

For Alembic Limited


Drigesh Mittal
Company Secretary



Encl.: A/a

ALEMBIC LIMITED

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2022

Sr. No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Revenue from Operations	3,061	3,742	1,915	9,013	5,998	7,822
2	Other Income	244	5,908	190	6,223	8,478	8,918
3	Total Income	3,305	9,650	2,106	15,235	14,476	16,740
4	Expenses						
	Cost of Materials Consumed	137	236	245	568	649	853
	Cost of Construction	797	1,263	409	2,521	909	1,164
	Changes in Inventories of Finished Goods and WIP	(7)	(109)	(89)	(119)	280	246
	Employee Benefit Expenses	589	634	496	1,844	1,603	2,147
	Finance Costs	11	12	7	34	29	39
	Depreciation and amortisation expense	169	167	118	503	346	486
	Other Expenses	503	614	490	1,509	1,457	2,020
	Total Expenses	2,198	2,816	1,676	6,859	5,272	6,954
5	Profit Before Tax	1,108	6,833	430	8,376	9,204	9,786
6	Tax Expenses						
	Current Tax	31	436	27	502	1,006	1,160
	Deferred Tax	(5)	273	(9)	283	44	21
	Short / (Excess) Provision of earlier years	(0)	-	-	(0)	-	(14)
7	Net Profit after tax for the Period	1,082	6,124	412	7,592	8,154	8,619
8	Share of Associate's Profit/(Loss)	3,480	5,409	4,781	6,648	13,961	13,586
9	Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)	4,562	11,533	5,192	14,240	22,115	22,206
10	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Profit or (Loss)	(4,328)	(1,407)	8,385	(13,136)	11,019	11,897
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	495	167	(957)	1,503	(1,246)	(1,344)
	B (i) Items that will be reclassified to Profit or (Loss)	91	147	4	417	49	132
11	Total Comprehensive Income/(Loss) for the Period	819	10,441	12,625	3,023	31,937	32,891
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)						1,89,567
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	1.78	4.49	2.02	5.55	8.61	8.65



Alembic Limited

Segment wise Consolidated Revenue and Results



Rs. in Lakhs

Sr. No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Segment Revenue						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	555	674	595	1,959	2,528	3,227
	b. Real Estate Business	2,506	3,068	1,321	7,054	3,470	4,595
	Total Income from Operations (Net)	3,061	3,742	1,915	9,013	5,998	7,822
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)						
	a. Active Pharmaceutical Ingredients Business	8	46	98	182	323	525
	b. Real Estate Business	1,024	971	292	2,348	839	1,162
	Total	1,032	1,017	391	2,530	1,162	1,687
	Unallocable Income and Expenditure						
	(i) Interest Expense	(11)	(12)	(7)	(34)	(29)	(39)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	46	5,781	(1)	5,777	8,017	7,960
	(iii) Other Income / (Expense)	41	48	46	102	54	178
	Total Profit Before Tax	1,108	6,833	430	8,376	9,204	9,786
3	Segment Assets						
	a. Active Pharmaceutical Ingredients Business	15,214	15,318	14,684	15,214	14,684	14,883
	b. Real Estate Business	29,776	28,883	25,000	29,776	25,000	27,248
	c. Unallocated	2,10,269	2,11,741	2,26,033	2,10,269	2,26,033	2,21,065
	Total	2,55,258	2,55,942	2,65,718	2,55,258	2,65,718	2,63,195
4	Segment Liabilities						
	a. Active Pharmaceutical Ingredients Business	1,770	2,389	1,842	1,770	1,842	1,752
	b. Real Estate Business	6,050	6,418	4,481	6,050	4,481	5,533
	c. Unallocated	4,993	5,508	6,090	4,993	6,090	6,251
	Total	12,813	14,315	12,412	12,813	12,412	13,537

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 9th February, 2023



For Alembic Limited

Chirayu Amin
Chirayu Amin
Chairman

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2022

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Revenue from Operations	2,954	3,639	1,860	8,706	5,858	7,597
2	Other Income	237	5,906	190	6,214	8,477	8,909
3	Total Income	3,191	9,545	2,050	14,920	14,334	16,506
4	Expenses						
	Cost of Materials Consumed	137	236	245	568	649	853
	Cost of Construction	797	1,263	409	2,521	909	1,164
	Changes in Inventories of Finished Goods and WIP	(7)	(109)	(89)	(119)	280	246
	Employee Benefit Expenses	589	634	496	1,844	1,603	2,147
	Finance Costs	3	4	3	11	20	23
	Depreciation and amortisation expense	160	158	109	475	319	450
	Other Expenses	455	569	469	1,369	1,405	1,896
	Total Expenses	2,133	2,755	1,643	6,670	5,183	6,779
5	Profit Before Tax	1,058	6,790	407	8,251	9,151	9,728
6	Tax Expenses						
	Current Tax	17	427	21	469	998	1,150
	Deferred Tax	(4)	273	(9)	284	44	21
	Short / (Excess) Provision of earlier years	-	-	-	-	-	(15)
7	Net Profit after tax for the Period	1,045	6,090	395	7,498	8,109	8,571
8	Other Comprehensive Income						
	(i) Items that will not be reclassified to Profit or (Loss)	(4,323)	(1,438)	8,390	(13,134)	11,037	12,009
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	494	168	(958)	1,502	(1,249)	(1,364)
9	Total Comprehensive Income/(Loss) for the Period	(2,784)	4,820	7,827	(4,133)	17,898	19,217
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)						41,294
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.41	2.37	0.15	2.92	3.16	3.34




Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
1	Segment Revenue						
	Revenue from Operations						
	a. Active Pharmaceutical Ingredients Business	555	674	595	1,959	2,528	3,227
	b. Real Estate Business	2,399	2,964	1,266	6,747	3,329	4,371
	Total Income from Operations (Net)	2,954	3,639	1,860	8,706	5,858	7,597
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)						
	a. Active Pharmaceutical Ingredients Business	8	46	98	182	323	525
	b. Real Estate Business	966	920	267	2,200	776	1,088
	Total	974	966	365	2,382	1,099	1,613
	Unallocable Income and Expenditure						
	(i) Interest Expense	(3)	(4)	(3)	(11)	(20)	(23)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	46	5,781	(1)	5,777	8,017	7,960
	(iii) Other Income / (Expense)	41	48	46	102	54	178
	Total Profit Before Tax	1,058	6,790	407	8,251	9,151	9,728
3	Segment Assets						
	a. Active Pharmaceutical Ingredients Business	15,214	15,318	14,684	15,214	14,684	14,883
	b. Real Estate Business	29,106	28,060	24,014	29,106	24,014	26,434
	c. Unallocated	60,608	65,894	73,351	60,608	73,351	73,102
	Total	1,04,927	1,09,272	1,12,049	1,04,927	1,12,049	1,14,419
4	Segment Liabilities						
	a. Active Pharmaceutical Ingredients Business	1,770	2,389	1,842	1,770	1,842	1,752
	b. Real Estate Business	5,516	5,884	4,002	5,516	4,002	4,972
	c. Unallocated	5,011	5,585	6,140	5,011	6,140	6,309
	Total	12,297	13,858	11,983	12,297	11,983	13,034

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited


Chirayu Amin
ChairmanPlace : Vadodara
Date : 9th February, 2023

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31st December, 2022 and year to date from 01st April, 2022 to 31st December, 2022 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

4. The statement includes results of the following entities:

- i. Alembic City Limited (Subsidiary)
- ii. Alembic Pharmaceuticals Limited (Associate)


5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflect total revenue of Rs. 420.89 lakhs and Rs. 1,214.95 lakhs, total net loss after tax of Rs. 21.88 Lakhs and total net loss after tax Rs. 91.78 lakhs and total comprehensive loss of Rs. 21.97 Lakhs and total comprehensive loss of Rs. 92.12 lakhs for the quarter ended 31st December, 2022 and the period ended on that day respectively. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 3,479.51 Lakhs and Rs. 6,647.95 lakhs and total comprehensive income of Rs. 3,565.70 lakhs and Rs. 7,062.62 lakhs for the quarter ended 31st December, 2022 and the period ended on that day respectively, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on statement is not modified with respect of the above matter.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Alok Shah

Partner

Membership No.042005

Place: Vadodara

Date: 9th February, 2023


UDIN: 23042005BG5QTU1920



Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 31st December, 2022 and year to date from 01st April, 2022 to 31st December, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036

Alok Shah

Alok Shah
Partner
Membership No.042005
Place: Vadodara
Date: 9th February, 2023
UDIN: 23042005BGSQTT7972

